西部制药服务公司（纽约证券交易所代码：WST）从经纪商那里获得313.00美元的平均目标价_新浪财经

West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) has been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $313.00.

A number of analysts recently weighed in on WST shares. KeyCorp increased their price target on shares of West Pharmaceutical Services from $315.00 to $375.00 and gave the company an "overweight" rating in a research report on Friday, February 17th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of West Pharmaceutical Services from $250.00 to $290.00 in a research report on Wednesday, February 22nd. Stephens raised shares of West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $330.00 to $400.00 in a research report on Tuesday. Finally, StockNews.com started coverage on shares of West Pharmaceutical Services in a research report on Thursday, March 16th. They issued a "hold" rating on the stock.

Get

West Pharmaceutical Services

alerts:

Insiders Place Their Bets

In other news, SVP Silji Abraham sold 1,500 shares of the company's stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $322.57, for a total transaction of $483,855.00. Following the completion of the sale, the senior vice president now directly owns 4,209 shares in the company, valued at approximately $1,357,697.13. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, SVP Silji Abraham sold 1,500 shares of the company's stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $322.57, for a total transaction of $483,855.00. Following the completion of the sale, the senior vice president now directly owns 4,209 shares in the company, valued at approximately $1,357,697.13. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Eric Mark Green sold 44,000 shares of the company's stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $322.35, for a total transaction of $14,183,400.00. Following the transaction, the chief executive officer now owns 85,705 shares of the company's stock, valued at $27,627,006.75. The disclosure for this sale can be found here. Company insiders own 1.13% of the company's stock.

Institutional Trading of West Pharmaceutical Services

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WST. Janiczek Wealth Management LLC increased its stake in West Pharmaceutical Services by 103.6% in the fourth quarter. Janiczek Wealth Management LLC now owns 112 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 57 shares in the last quarter. Guardian Wealth Advisors LLC acquired a new stake in West Pharmaceutical Services in the third quarter valued at approximately $29,000. Householder Group Estate & Retirement Specialist LLC acquired a new stake in West Pharmaceutical Services in the third quarter valued at approximately $36,000. Private Trust Co. NA lifted its stake in shares of West Pharmaceutical Services by 194.6% in the third quarter. Private Trust Co. NA now owns 165 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 109 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its stake in shares of West Pharmaceutical Services by 151.4% in the first quarter. Massmutual Trust Co. FSB ADV now owns 186 shares of the medical instruments supplier's stock valued at $64,000 after buying an additional 112 shares in the last quarter. Institutional investors and hedge funds own 91.51% of the company's stock.

West Pharmaceutical Services Trading Up 2.2 %

Shares of NYSE WST opened at $366.74 on Tuesday. West Pharmaceutical Services has a 1-year low of $206.19 and a 1-year high of $390.62. The company has a market cap of $27.24 billion, a PE ratio of 47.51, a P/E/G ratio of 3.15 and a beta of 1.09. The company has a current ratio of 3.70, a quick ratio of 2.90 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average of $319.76 and a two-hundred day moving average of $268.87.

West Pharmaceutical Services (NYSE:WST – Get Rating) last issued its earnings results on Thursday, February 16th. The medical instruments supplier reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.38. The company had revenue of $708.70 million for the quarter, compared to analyst estimates of $657.16 million. West Pharmaceutical Services had a net margin of 20.30% and a return on equity of 26.24%. The company's revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.04 EPS. As a group, equities analysts expect that West Pharmaceutical Services will post 7.38 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 3rd. Shareholders of record on Wednesday, April 26th will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Tuesday, April 25th. This represents a $0.76 dividend on an annualized basis and a yield of 0.21%. West Pharmaceutical Services's dividend payout ratio (DPR) is 9.84%.

About West Pharmaceutical Services

(Get Rating)

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
Delta Airlines Is Ready To Fly Higher
Global Payments Climbs After Goldman Sachs Upgrade
Fastenal Is At A Critical Turning Point
3 Healthcare Stocks Insiders Are Buying
Novo Nordisk Charges Higher and Could be Just Getting Started

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.